TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

Multiple Sclerosis
TG announces strong top-line Phase III data for ublituximab in multiple sclerosis. • Source: Shutterstock

With Phase III top-line data for CD20-targeting monoclonal antibody ublituximab showing a marked improvement in relapse rates in relapsing multiple sclerosis (RMS), TG Therapeutics, Inc.’s drug may be able to compete with other therapies on a shorter infusion time and pricing.

The company said it is planning to file for US Food and Drug Administration approval of ublituximab in the middle...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category